Conference Coverage

Chlamydia infections associated with more than a doubling of ovarian cancer risk

Publish date: March 16, 2018

 

FROM THE AACR ANNUAL MEETING


Neither cohort showed any significant association of ovarian cancer with any of the other antibodies, Dr. Trabert said.

The NCI Intramural Research Program supported the study. Dr. Trabert and her colleagues declared no conflicts of interest.

SOURCE: Trabert et al. Abstract 4942.

Pages

Recommended Reading

FDA: Laparoscopic power morcellators can spread malignant cells when used in women with occult uterine cancers*
MDedge Hematology and Oncology
Age at RRSO affects peritoneal cancer risk in BRCA mutation carriers
MDedge Hematology and Oncology
HIPEC shows survival benefit for advanced ovarian cancer
MDedge Hematology and Oncology
New multi-analyte blood test shows promise in screening for several common solid tumors
MDedge Hematology and Oncology
Experimental PD-1/PARP inhibitor combo shows promise in solid tumors
MDedge Hematology and Oncology
Pembrolizumab plus SBRT shows promise for advanced solid tumors
MDedge Hematology and Oncology
Letrozole promising as maintenance treatment for high-grade serous ovarian cancer
MDedge Hematology and Oncology
USPSTF: Routine screens for ovarian cancer not recommended
MDedge Hematology and Oncology
Avelumab safety compares with other checkpoint inhibitors
MDedge Hematology and Oncology
FDA authorizes first direct-to-consumer BRCA1/2 test
MDedge Hematology and Oncology